NICE recommends apixiban and ranibizumab . . .
- PDF / 114,254 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 13 Downloads / 209 Views
. . but pemetrexed doesn’t make the cut However, in draft guidance, NICE has said it will not recommend pemetrexed [Alimta] for the maintenance treatment of non-small cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin.3 At a cost of over £76 300 per QALY, NICE did not consider this treatment a cost effective use of NHS resources. NICE has already recommended pemetrexed as a first-line treatment option for NSCLC and as a maintenance treatment option following platinumbased chemotherapy in combination with gemcitabine, paclitaxel or docetaxel. * incremental cost-effectiveness ratio 1. NICE. NICE recommends new treatment option for people with common heart condition - 27 February 2013. Media Release : 27 Feb 2013. Available from: URL: http://www.nice.org.uk. 2. NICE. NICE gives green light to ranibizumab for diabetic macular oedema in final guidance after rapid review. Media Release : 27 Feb 2013. Available from: URL: http://www.nice.org.uk. 3. NICE. NICE consults on pemetrexed for the maintenance treatment of nonsmall-celllung cancer. Media Release : 21 Feb 2013. Available from: URL: http://www.nice.org.uk. 801085656
1173-5503/10/0673-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 9 Mar 2013 No. 673
1
Data Loading...
